Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | GLP1R | P43220 | 6/20 | 0.46 |
| ▸ | GIPR | P48546 | 6/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018606 | 0.98 | OPRD1 (0.48) | BCL2L1OPRD1OPRM1OPRK1KEAP1 | |
| SCHEMBL22018500 | 0.95 | APLNR (0.49) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL22018605 | 0.94 | NPY2R (0.51) | OPRD1OPRM1OPRK1F2TFPI | |
| SCHEMBL25524956 | 0.94 | NMUR2 (0.51) | KEAP1F2TFPI | |
| SCHEMBL22380728 | 0.94 | APLNR (0.44) | BCL2L1OPRD1OPRM1OPRK1GLP1R | |
| SCHEMBL22018604 | 0.93 | APLNR (0.45) | OPRD1OPRM1OPRK1 | |
| SCHEMBL22018361 | 0.92 | APLNR (0.46) | OPRD1OPRM1OPRK1F2TFPI | |
| SCHEMBL22018477 | 0.92 | APLNR (0.46) | OPRD1OPRM1OPRK1TFPI | |
| SCHEMBL22922932 | 0.92 | APLNR (0.46) | OPRD1OPRM1OPRK1TFPI | |
| SCHEMBL22018503 | 0.91 | NTSR1 (0.51) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | BCL2L1 994/4885OPRD1 3752/4885OPRM1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.